Home >

Icotinib (Conmana)

Last Updated: 03/13/18

Status: Currently a NF2 Clinical Trial

Chemical Structure, Icotinib

Trade Name: Conmana
Synonyms: Icotinib hydrochloride (BPI-2009H), 610798-31-7, Conmana, BPI-2009, UNII-9G6U5L461Q, BPI-2009H,
CHEMBL2087361, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine,
Pharmaceutical Company:
Legal Status: ℞ - Prescription, in China, Beijing
Administered By: Pill - Oral
Tumor Target: NF2 Vestibular Schwannoma, solid tumors
Protein Target: Epidermal Growth Factor Receptor -
Tyrosine Kinase Inhibitor (EGFR-TKI)
Formula: C22H22ClN3O4
NF2 Trial: Recruiting Trial: NCT02934256
PubChem CID 44609731
ChemSpider 28637803


  1. Peng, Li. ClinicalTrials.gov. NIH - U. National Library of Medicine. "Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors" (2016) Clinical Trials.
    Source: https://clinicaltrials.gov/ct2/show/NCT02934256
  2. Hu, Shaojing, et al. Bioorganic & medicinal chemistry letters "Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors." 22.19 (2012): 6301-6305.
    Source: https://www.sciencedirect.com/science/article/pii/S0960894X12008189 | DOI: 10.1016/j.bmcl.2012.06.067
What is NF2? | About Us | Treatment Options | Sitemap

Site Search

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2021